Current State of Using Botulinum Toxin in Pediatric Urology. Literature Review
Author(s)
Romashin Maksim A. , Guseva N.B , Mlynchik E.V , Ignatyev R.O ,
Download Full PDF Pages: 78-82 | Views: 341 | Downloads: 82 | DOI: 10.5281/zenodo.6593240
Abstract
Botulinum Toxin Type A (BTTA) was first used in medicine in the late 1960s.During its relatively short history, botulinum toxin has found application in various fields of medicine such as urology, neurology, ophthalmology, gastroenterology, pediatrics, endocrinology, otorhinolaryngology, proctology, and others. However, the use of this toxin in pediatric urology began only in 2003. BTTA is mainly used to treat neurogenic urinary disorders (urinary incontinence), most of which are caused by myelodysplasia. It is difficult to overestimate the importance of chemodenervation with botulinum toxin in children with gallbladder-dependent hydroureteronephrosis, since if conservative treatment is unsuccessful, such children undergo traumatic augmentation surgeries with adverse long-term consequences, and chemodenervation is the last line of therapy in these patients. It should also be noted that although the data on detrusor denervation efficacy by botulinum toxin are very promising, there are no clear indications for intervention. This study was conducted with the aim of reviewing and interpreting the currently existing information on the use of BTTA in pediatric urology.
Keywords
botulinum toxin type A, children, urinary incontinence, myelodysplasia.
References
i. Jabbari B. History of botulinum toxin treatment in movement disorders. Tremor Other Hyperkinet Mov (NY) 2016; 6: 394 DOI: 10.7916/D81836S1
ii. Monheit G.D., Pickett A. AbobotulinumtoxinA: A 25-year history. Aesthet Surg J 2017; 37 (Suppl. 1): 4–11. DOI: 10.1093/asj/sjw284
iii. Peck M.W., Smith T.J., Anniballi F., et al. Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins (Basel) 2017; 9 (1): 38 DOI: 10.3390/toxins9010038
iv. Pirazzini M., Rossetto O., Eleopra R., Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 2017; 69 (2): 200–35. DOI: 10.1124/pr.116.012658
v. Lazishvili M.N. Efferent methods of treatment of neurogenic urinary tract dysfunction in children with myelodysplasia. Moscow, 2014
vi. Guseva N.B., Ignatiev R.O. Myelodysplasia in children (organization and provision of specialized medical care): a guide for doctors. Ed. Rozinov V.M. Moscow: Tradition, 2017
vii. Danilov V.V., Danilov V.V. Neurourology: in 3 volumes. Vladivostok: Directors Club, 2019, Vol. 1
viii. Lee Y.K., Kuo H.C. Therapeutic effects of botulinum toxin A, via urethral sphincter injection on voiding dysfunction due to different bladder and urethral sphincter dysfunctions. Toxins (Basel) 2019; 11 (9): 487 DOI: 10.3390/toxins11090487
ix. Multani I., Manji J., Hastings-Ison T. et al. Botulinum toxin in the management of children with cerebral palsy. Paediatr Drugs 2019; 21 (4): 261–81. DOI: 10.1007/s40272-019-00344-8
x. Sager C., Burek C., Durán V. et al. Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type A. ISRN Urol 2012; 2012: 763159 DOI: 10.5402/2012/763159
xi. Sakalis V.I., Oliver R., Guy P.J., Davies M.C. Macroplastique and botox are superior to macroplastique alone in the management of neurogenic vesicoureteric reflux in spinal cord injury population with presumed healthy bladders. J Spinal Cord Med 2019; 42 (4): 478–84. DOI: 10.1080/10790268.2018.1433266
xii. Tyagi P., Kashyap M., Yoshimura N. et al. Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder. J Urol 2017; 197 (4): 982–90. DOI: 10.1016/j.juro.2016.11.092
xiii. Wu S.J., Xu Y.Q., Gao Z.Y. et al. Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis. Ren Fail 2019; 41 (1): 937–45. DOI: 10.1080/0886022X.2019.1655448
xiv. Kuo Y.C., Kuo H.C. Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis-different mechanisms of action of botox on bladder dysfunction? Toxins (Basel) 2016; 8 (3): 75 DOI: 10.3390/toxins8030075
xv. Kaviani A., Khavari R. Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity. Urol Clin North Am 2017; 44 (3): 463–74. DOI: 10.1016/j.ucl.2017.04.012
xvi. Chuang Y.C., Kaufmann J.H., Chancellor D.D. et al. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol 2014; 192 (6): 1743–9. DOI: 10.1016/j.juro.2014.07.008
xvii. Janicki J.J., Chancellor M.B., Kaufman J. et al. Potential effect of liposomes and liposome-encapsulated botulinum toxin and tacrolimus in the treatment of bladder dysfunction. Toxins (Basel) 2016; 8 (3):81. DOI: 10.3390/toxins8030081
Cite this Article: